LifeMD (NASDAQ:LFMD) Price Target Increased to $14.00 by Analysts at BTIG Research

LifeMD (NASDAQ:LFMD - Free Report) had its price target hoisted by BTIG Research from $13.00 to $14.00 in a research note issued to investors on Tuesday, Benzinga reports. BTIG Research currently has a buy rating on the stock.

Separately, HC Wainwright raised their price target on LifeMD from $10.00 to $12.00 and gave the stock a buy rating in a report on Thursday, January 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, LifeMD presently has an average rating of Buy and a consensus target price of $10.40.

LifeMD Stock Performance

NASDAQ:LFMD traded up $0.89 during trading hours on Tuesday, reaching $10.89. 1,113,060 shares of the stock were exchanged, compared to its average volume of 822,923. The company has a quick ratio of 1.15, a current ratio of 1.22 and a debt-to-equity ratio of 3.22. The firm has a 50 day simple moving average of $9.06 and a 200-day simple moving average of $7.64. LifeMD has a 52 week low of $1.40 and a 52 week high of $12.01. The stock has a market capitalization of $439.63 million, a P/E ratio of -15.64 and a beta of 1.43.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its earnings results on Monday, March 11th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The firm had revenue of $44.86 million for the quarter, compared to the consensus estimate of $40.65 million. As a group, sell-side analysts forecast that LifeMD will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of LifeMD

Several hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC raised its stake in LifeMD by 266.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company's stock valued at $38,000 after acquiring an additional 3,348 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in LifeMD by 24.8% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 25,200 shares of the company's stock valued at $158,000 after acquiring an additional 5,000 shares in the last quarter. Dorsey Wright & Associates bought a new stake in LifeMD during the 3rd quarter valued at $37,000. HighMark Wealth Management LLC bought a new stake in LifeMD during the 3rd quarter valued at $38,000. Finally, Worth Venture Partners LLC bought a new stake in LifeMD during the 3rd quarter valued at $64,000. Institutional investors own 35.52% of the company's stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.